Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05017883
Other study ID # V2.0
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 1, 2021
Est. completion date October 2025

Study information

Verified date August 2021
Source PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Contact Xingbing Wang
Phone 13856007984
Email wangxingbing@ustc.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a clinical study of ytaa05 cell injection in the treatment of patients with recurrent / refractory acute myeloid leukemia.The purpose is to evaluate the safety and preliminary efficacy of FLT3 car-t cells in patients with recurrent / refractory FLT3 positive acute myeloid leukemia.#TAA05 cell injection is a T cell targeting FLT3 chimeric antigen receptor#


Description:

Acute myeloid leukemia (AML) is a hematological malignancy caused by abnormal differentiation and uncontrolled proliferation of hematopoietic progenitor cells. If AML is not given active treatment within one year after diagnosis, it will cause fatal infection, bleeding and organ infiltration due to abnormal proliferation of tumor cells. AML is one of the most common leukemia. About 3.8 patients in every 100000 people are in the higher incidence rate among people aged 65 and over, and 17.9 patients in every 100000 people. The cure rate of AML is about 35-40% in patients ≤ 60 years old and only 5-15% in patients over 60 years old. The survival of elderly patients who can not tolerate chemotherapy is frustrating, and the median survival time is only 5-10 months. In the past 20 to 30 years, the treatment of acute myeloid leukemia (AML) has made significant progress, so that about 80% of adult patients under the age of 55 can achieve complete remission. However, more than half of Cr patients will relapse, and the long-term survival rate is about 40%. Until the 1970s, diagnosis was only based on pathological and cytological examination of bone marrow and blood. The five-year survival rate was less than 15%. CAR-T cells can recognize specific antigens in a non restricted manner of HLA and continuously activate T cells. FLT3 is a potential target of AML. Therefore, the construction of car-t cells that recognize human FLT3 molecule has high clinical value in the treatment of AML.


Recruitment information / eligibility

Status Recruiting
Enrollment 5
Est. completion date October 2025
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Age 18 ~ 70 years old (including boundary value), regardless of gender; 2. Acute myeloid leukemia with FLT3 positive (positive rate = 30%) verified by flow cytometry or immunohistochemistry; 3. The expected survival time was more than 12 weeks; 4. ECoG score 0-2; 5. Refractory or relapse after standardized treatment; 6. Liver and kidney function and cardiopulmonary function meet the following requirements: 1. Creatinine = 1.5 ULN; 2. Left ventricular ejection fraction = 45%; 3. Blood oxygen saturation > 91%; 4. Total bilirubin = 1.5 × ULN; ALT and AST = 2.5 × ULN; 7. Understand the test and have signed the informed consent form. Exclusion Criteria: 1. Patients with graft-versus-host disease (GVHD) or requiring immunosuppressive agents; 2. Malignant tumors other than acute myeloid leukemia within 5 years before screening, except fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical operation, and breast ductal carcinoma in situ after radical operation; 3. hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection is not within the normal reference range; Hepatitis C virus (HCV) antibody positive and hepatitis C virus (HCV) RNA positive in peripheral blood; Human immunodeficiency virus (HIV) antibody positive; Cytomegalovirus (CMV) DNA positive; Syphilis test positive; 4. Severe heart disease: including but not limited to unstable angina pectoris, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification = grade III), severe arrhythmia; 5. Unstable systemic diseases judged by the researcher: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment; 6. Within 7 days before screening, there were active or uncontrollable infections requiring systemic treatment (except mild urogenital infection and upper respiratory tract infection); 7. Pregnant or lactating women, female subjects who planned pregnancy within 1 year after cell reinfusion, or male subjects whose partners planned pregnancy within 1 year after cell reinfusion; 8. Those who had received car-t therapy or other gene modified cell therapy before screening; 9. Subjects who were receiving systemic steroid treatment within 7 days before screening or who were determined by the investigator to need long-term systemic steroid treatment during treatment (except inhalation or local use); 10. Participated in other clinical studies within 3 months before screening; 11. There was evidence of central nervous system invasion during subject screening; 12. According to the judgment of the researcher, it does not conform to the situation of cell preparation; 13. Other researchers believe that it is not suitable for inclusion.

Study Design


Intervention

Drug:
TAA05 cell injection
Chimeric antigen receptor T cells (car-t) Chimeric antigen receptor T cells (car-t) is one of the most effective therapies for malignant tumors (especially hematological tumors). Like other immunotherapies, the basic principle is to use the patient's own immune cells to clear cancer cells. Chimeric antigen receptor (car) is the core component of car-t, which endows T cells with the ability to recognize tumor antigens in an independent manner,which enables car modified T cells to recognize a wider range of targets than natural T cell surface receptors (TCR). The basic design of car includes a tumor associated antigen binding region (usually derived from scFv segment of monoclonal antibody antigen binding region), transmembrane region and intracellular signal region. The selection of target antigen is a key determinant for the specificity and effectiveness of car and the safety of genetically modified T cells.

Locations

Country Name City State
China Anhui Provincial Hospital Hefei Anhui

Sponsors (2)

Lead Sponsor Collaborator
PersonGen BioTherapeutics (Suzhou) Co., Ltd. Anhui Provincial Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary ORR 3 ORR 3 3-month objective response rate three months after CAR-T cells infusion
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2